FDA-Drug2026-04-22Class IIPROCESSING DEFECT
Payless Compounders semaglutide injectable recalled for sterility concerns
Stop using Payless Compounders semaglutide injections
Payless Compounders is recalling a compounded semaglutide injection due to lack of assurance of sterility. The affected product is a 0.5 mL vial from lot 01-27-2026@14S.5 distributed in Oregon. No injuries have been reported so far.
- Stop using this product immediately if you have it
- Contact your pharmacy or healthcare provider with the lot number
- Do not use remaining doses from the affected lot
- Ask your provider about alternative treatment options
Hazard
Lack of Assurance of Sterility
Who it affects
Adults
Illnesses reported
None reported
Sold states
OR
Affected count
91 vials
Manufactured in
8505 Sw Creekside Pl Ste 110, N/A, Beaverton, OR, United States
Products
Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0471-2026Don't want to check this manually?
We email you a Sunday digest of new federal recalls relevant to your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.
Get the Sunday Brief